Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Durzyńska, Julia; Błażejewska, Paulina; Szydłowski, Jarosław; Goździcka-Józefiak, Anna

doi:10.1089/vim.2010.0014

Cited by 5 publications

(3 citation statements)

References 41 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the study by Buchinsky et al, almost half (47%) of adult and adolescent participants with a median (range) duration of symptoms of 11 (1-69) years possessed no antibodies against HPV-6 and HPV-11. The proportion of seropositive people with RRP according to some studies may be positively correlated with the duration of symptomatic disease and the number of surgery-necessitating interventions . The duration of the disease before enrollment was slightly shorter in our study in comparison with that of Buchinsky et al, so the higher percentage of seropositive patients may be more likely attributable to the use of diverse methods for antibody level testing.…”

Section: Discussioncontrasting

confidence: 43%

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

Smahelova

Hamšíková

Ludvı́ková

et al. 2022

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

IMPORTANCE Recurrent respiratory papillomatosis (RRP) is a rare benign chronic disease of the larynx etiologically linked with the infection of low-risk human papillomavirus (HPV). Combination of surgical and immunomodulatory therapy has limited success. Possible use of prophylactic HPV vaccine that includes HPV-6 and HPV-11 antigens has been studied. OBJECTIVE To evaluate if the HPV vaccination is associated with a lower number of recurrences requiring surgical intervention in patients with new and recurrent RRP. DESIGN, SETTING, AND PARTICIPANTSThis was a non-placebo-controlled intervention study. Enrollment data were collected from October 2011 to August 2013. The patients were followed up at 1 month, 12 months, and 5 years after the third dose of the vaccine and clinically monitored until December 31, 2018. Data were analyzed from 2019 to 2021. Altogether, 50 adults with active RRP were enrolled and followed up in referral centers. For the final outcome, follow-up data for 42 patients were available. Eight patients who did not fulfill the protocol were excluded.INTERVENTIONS All patients received HPV vaccine as an adjuvant treatment and were clinically followed up. When RRP progression or a significant recurrent lesion was detected, surgical removal via direct laryngoscopy was indicated. No adjuvant therapy with antiviral or biological agents was used. MAIN OUTCOMES AND MEASURESThis study compared the prevaccination and postvaccination positivity for HPV-specific antibodies. The main outcome was the difference in the frequency of RRP recurrences in the prevaccination and postvaccination period.RESULTS A total of 50 patients with RRP were enrolled (median [SD] age, 41.5 [12.3] years [range,; 39 [78%] men and 11 [22%] women). After HPV vaccination, patients with previously no HPV-specific antibodies showed seroconversion, and all patients developed 100-fold higher levels of HPV vaccine type-specific antibodies compared with the prevaccination period. In patients with recurrent RRP, decreased frequency of recurrences requiring surgical treatment was present after vaccination (from 0.85 to 0.36 recurrences/y). No difference in postvaccination recurrences was found between patients with newly diagnosed and recurrent RRP. CONCLUSIONS AND RELEVANCEIn this nonrandomized clinical trial, the frequency of RRP recurrences was significantly lower after HPV vaccination, and patients with RRP thus had a reduced burden of disease. Because no difference was detected in the frequency of recurrent postvaccination lesions in patients with new and recurrent disease, it appears that both groups showed equal benefit following HPV vaccination. These findings suggest that the earlier that patients with RRP receive HPV vaccine, the sooner they may show reduced burden of disease.

show abstract

Section: Discussioncontrasting

confidence: 43%

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

Smahelova

Hamšíková

Ludvı́ková

et al. 2022

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…In our concurrent study, HPV-6 genotype has been identified in 30% cases of juvenile-onset recurrent respiratory papillomatosis among 47 patients investigated (3–12 year old) [6]. Concordant results concerning high HPV-11 prevalence in normal oral mucosa were not reported in literature.…”

Section: Discussionmentioning

confidence: 85%

HPV genotypes in the oral cavity/oropharynx of children and adolescents: cross-sectional survey in Poland

et al. 2010

Self Cite

View full text Add to dashboard Cite

Human papillomaviruses (HPVs) are a very complex group of pathogenic viruses, with more than 80 types, causing human infection. Given the prevalence of HPV infection and its relationship with the development of cervical and many other cancers, HPV vaccine development has been a major public health initiative worldwide in the last decade. The aim of the presented study was to identify HPV DNA by MY-PCR in 4,150 school children and adolescents, aged 10–18 years in the Wielkopolska region, Poland. All individuals were asked to fill in extensive questionnaires; further normal, oral squamous cells were collected from each pupil. Cellular DNA was isolated and used as a MY-PCR template to estimate the incidence of HPV-active infection. Forty five subjects (1.08% of the sample) were carriers of oropharyngeal HPVs. HPV status and variables of interest, such as age, gender, socioeconomical status, and risk factors (smoking and sexual intercourse history, alcohol consumption) were not correlated. The presence of HPVs in the oral cavity was cumulated in several schools of the region. DNA sequencing of MY-PCR products revealed only four HPV genotypes. The most frequent genotype was HPV11 (38/45 HPV-positive cases), while other more rare genotypes were HPV6 (3/45), HPV12 (3/45), and HPV57 (1/45). Conclusion: Our findings presented herein, reveal a relatively low prevalance of oropharyngeal HPVs in Polish adolescents and fill an important gap in the knowledge of oral HPV infections of children above 10 years and adolescents.

show abstract

“…Duration and surgical count correlated with seronegative vs seropositive but not with titre given seropositivity. We were thus surprised when Durzyńska et al [25] reported a very tight correlation between ELISA absorbance and surgical count; an extraordinary 87% of the variance in absorbance could be predicted by the variance in surgical count. They only tested anti-HPV11 and 30% of their 47 subjects were not infected with HPV11.…”

Section: Plos Onementioning

confidence: 95%

In RRP, serologic response to HPV is frequently absent and slow to develop

et al. 2020

View full text Add to dashboard Cite

BackgroundRecurrent respiratory papillomatosis (RRP) is characterized by repeated formation of papillomas in the respiratory tract and is caused by human papillomavirus (HPV) types 6 and 11. Women with genital HPV infection are slow to develop weak humoral immunity, but respond robustly to the HPV vaccine. We wondered if people with RRP had a similar immune response. MethodsA convenience cross-sectional sample of patients with RRP were recruited into one of four groups: 1) adults and adolescents with active RRP, 2) children with active RRP, 3) RRP patients who had undergone HPV vaccination prior to enrollment and, 4) people with RRP who were in remission. Anti-HPV6 and HPV11 serology was determined by cLIA on a single blood draw. OPEN ACCESS Citation: Buchinsky FJ, Ruszkay N, Valentino W, Derkay CS, McClay JE, Bastian RW, et al. (2020) In RRP, serologic response to HPV is frequently absent and slow to develop. PLoS ONE 15(3): e0230106. https://doi. ConclusionPeople with RRP are capable of developing a humoral response to HPV6 and HPV11. That response appears to be robust when initiated by the HPV vaccine, but either nonexistent or slow to develop in response to infection. Most in remission do not have demonstrable antibody levels against HPV6 or HPV11.

show abstract

Detection of Anti-HPV11-L1 Antibodies in Immune Sera from Patients Suffering from Recurrent Respiratory Papillomatosis Using ELISA

Cited by 5 publications

References 41 publications

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

Outcomes After Human Papillomavirus Vaccination in Patients With Recurrent Respiratory Papillomatosis

HPV genotypes in the oral cavity/oropharynx of children and adolescents: cross-sectional survey in Poland

In RRP, serologic response to HPV is frequently absent and slow to develop

Contact Info

Product

Resources

About